Artificial intelligence-based disease detection technology company Viz.ai announced today that it raised $100 million in a Series D financing round.
San Francisco-based Viz.ai develops AI algorithms that detect disease and offer hospital systems a way to ensure that, once detected, the patients are captured, and workflows across an entire health system are standardized. The latest algorithm for detecting suspected cerebral aneurysms received FDA clearance in February.
According to a news release, the financing round comes on the back of the company reaching the milestone of more than 1,000 hospitals using the Viz Platform.
Tiger Global and Insight Partners led the financing round, while several early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV and Susa participated.
Viz.ai said in the release that the new funds will be used to support its growth trajectory as it seeks to expand the Viz Platform to detect and triage additional diseases while growing its customer base globally.
“Viz.ai is committed to helping patients get better, faster and more equitable access to life-saving treatments,” Viz.ai co-founder and CEO Chris Mansi said in the release. “We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
